



General Counterdrug Intelligence Plan Supplement July 2002

GCIP Revalidation

From February through May 2002, as part of the current Administration's overall counterdrug policy review led by the Director of National Drug Control Policy, all of the participating GCIP departments and agencies reviewed the GCIP program, with primary focus on the organizational and oversight mechanisms established by the GCIP to facilitate counterdrug intelligence coordination and issue resolution. As reported by the Director of National Drug Control Policy in a letter to the other seven participating Cabinet principals, the Review Group, made up of representatives of the eight Cabinet members and five heads of Federal counterdrug law enforcement agencies, concluded that the GCIP continues to be viable for improving coordination and cooperation among the various agencies and departments having diverse counterdrug intelligence responsibilities and functions. This review further concluded that the management and oversight structure set in place to assist departments and agencies in GCIP implementation efforts should be continued but modified and strengthened.

This supplement includes a copy of the *GCIP Policy Review* paper, dated May 20, 2002, that reported the results of the review process. This agreement, therefore, represents a supplement to Section A of the GCIP, which deals with the National Coordination construct -- specifically the interagency Counterdrug Intelligence Coordinating Group (CDICG) and its subordinate Counterdrug Intelligence Executive Secretariat (CDX) staff -- established for advancing the 73 action items outlined in the subsequent topical GCIP sections B through F.

Overall, during these first two years of GCIP implementation, participating agencies and components have made significant progress. Two-thirds of the original 73 action items have either been completed (44%) or have at least had substantial progress made toward their implementation (another 21%). The CDICG and CDX have additionally provided assistance on several new counterdrug intelligence "component referral" issues that representatives of GCIP-participating agencies brought before the CDICG since GCIP publication. To date 16 such component-referred issues were undertaken, with action completed on 11.

As a part of this *GCIP Policy Review*, the CDICG was charged with conducting a complete "scrub" of the remaining, uncompleted GCIP action items and component referrals, delineating those that should continue to be pursued as top priority for completion, those that should be pursued at more routine pace (medium priority), and those that could be deferred (low priority). The CDICG review was completed on July 2, 2002. The resultant re-prioritized remaining GCIP action items and component issue referrals are identified in the updated "Status of GCIP action items" table on the next page of this supplement.

Status of GCIP Action Items and Component Referrals - July 2002

This table depicts the status of all 73 original GCIP action items, and of the 16 new component referral issues undertaken to date since the publication of the GCIP. Approximately half of the items are those that the CDICG regards as either completed (C) or deferred (D). Items marked as deferred are those which the responsible components may elect to continue to pursue on their own, but which the CDICG categorizes as being of lower priority; no further CDICG/CDX staff or budget resources will be expended on them in the coming year. All of the remaining uncompleted items have been re-numbered -- in some cases with two or more re-grouped -- into 11 top priority (Level I) and 9 medium priority (Level II) action items. (For example, original GCIP action items C-13 and F-5 have now been consolidated into new top priority item I-8.)

<u>Item</u>	<u>Status</u>								
B-01	C	C-01	I-4	D-01	C	E-01	D	F-01	C
B-02	C	C-02	I-11	D-02	C	E-02	II-3	F-02	I-2
B-03	C	C-03	I-5	D-03	C	E-03	I-9	F-03	I-1
B-04	II-6	C-04	C	D-04	C	E-04	I-9	F-04	C
B-05	II-1	C-05	C	D-05	C	E-05	D	F-05	I-8
B-06	C	C-06	C	D-06	I-10	E-06	D	F-06	II-6
B-07	C	C-07	C	D-07	C	E-07	D	F-07	II-5
B-08	C	C-08	I-5	D-08	C	E-08	I-9	F-08	II-7
B-09	C	C-09	C	D-09	C	E-09	I-9	F-09	II-4
B-10	II-5	C-10	I-5	D-10	C	E-10	D	F-10	D
B-11	II-5	C-11	II-6	D-11	C	E-11	I-9		
B-12	I-3	C-12	C	D-12	II-2	E-12	C		
B-13	II-5	C-13	I-8			E-13	I-7		
B-14	D					E-14	I-6		
B-15	C					E-15	C		
B-16	C					E-16	D		
B-17	C					E-17	I-7		
B-18	C					E-18	I-11		
						E-19	I-9		
						E-20	C		

Component Referrals

Status

CR-01	Coordination of National and Worldwide threat assessments	C
CR-02	EPIC program resources alternatives	D
CR-03	Interagency support to Arrival Zone Threat Assessment	II-8
CR-04	DOCEX working group support	C
CR-05	Law enforcement input to ONDCP HIDTA guidelines	C
CR-06	JIATF-East intelligence sharing protocols	C
CR-07	CCDB releasability to UK	C
CR-08	Sponsorship of initial IC-law enforcement bilateral workshops	C
CR-09	Law enforcement tactical SIGINT review	C
CR-10	Outbound orientation pre-tour briefings	II-9
CR-11	Sponsorship of Interagency Overseas Operations Seminars	D
CR-12	Establishment of interagency Training Advisory Council	C
CR-13	Sponsorship of initial National Counterdrug Systems Conference	C
CR-14	Promotion of interagency NDIL/CPQ support	C
CR-15	Support to Linear designated target review initiative	C
CR-16	Support to LA regional Centers for Drug Information initiative	I-10